Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: Beyond the HORIZONS-AMI trial

Reviews in Cardiovascular Medicine

Volumn 10, Issue 2, 2009, Pages 72-82

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Bivalirudin; Myocardial infarction; Primary percutaneous coronary intervention; Stent thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG; PRASUGREL; THROMBOCYTE RECEPTOR; TIROFIBAN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; RECOMBINANT PROTEIN; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADD ON THERAPY; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY STENT; DRUG DOSE COMPARISON; DRUG FATALITY; HEART INFARCTION; HEART MUSCLE NECROSIS; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE; ADJUVANT CHEMOTHERAPY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RISK ASSESSMENT; THIOPHENES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 69249215464     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Wilentz JR, Sanborn TA, Haudenschild C, et al. Platelet accumulation in experimental angioplasty: time course in relation to vascular injury. Circulation. 1987;75:636-642. (Pubitemid 17026056)
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
3. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2: 535-545. (Pubitemid 39069789)
4. Mousa SA, Bennett JS. Platelets in health and disease: platelet GP IIb/IIIa structure and function: recent advances in antiplatelet therapy. Drugs Future. 1996;21:1141-1154.
5. Chakhtoura EY, Shamoon FE, Haft JI, et al. Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol. 2000;86:835-839.
6. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896-899. (Pubitemid 34925319)
7. Williams MS, Bush DE. Platelet hyperreactivity is present in acute coronary syndromes despite treatment with aspirin [abstract]. Circulation. 2003;108:IV-378.
8. Soffer D, Moussa I, Karatepe M, et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol. 2003;91:872-875. (Pubitemid 36363736)
9. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999;33:634-639.
10. Pizzulli L, Yang A, Martin JF, Luderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J. 1998;19:80-84. (Pubitemid 28112303)
11. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:743-749.
12. Kabbani SS, Watkins MW, Ashikaga T, et al. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol. 2003; 91:876-878. (Pubitemid 36363737)
13. Goncalves SC, Labinaz M, LeMay M, et al. Impact of mean platelet volume on clinical outcomes after percutaneous coronary intervention [abstract]. Am J Cardiol. 2008;102:23i.
14. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol. 2006;48:2178-2185. (Pubitemid 44873056)
15. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;46:284-290. (Pubitemid 40966857)
16. Miyamoto S, Kawano H, Kudoh T, et al. Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary intervention. Am J Cardiol. 2005;96:71-73. (Pubitemid 40853944)
17. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005;46:906-919. (Pubitemid 41226477)
18. Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol. 2004;43: 162-168. (Pubitemid 38201138)
19. Kleiman NS, Grazeiadei N, Maresh K, et al. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. Am Heart J. 2000;140:492-501.
20. Sabatine MS, Hamdalla HN, Mehta SR, et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008;155:910-917.
21. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol. 2003;42:1188-1195.
22. Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation. 2005;111:1153-1159.
23. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol. 2006;48:2186-2191.
24. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary intervention after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol. 2002;40: 662-668. (Pubitemid 34925612)
25. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006; 295:1531-1538.
26. Marciniak SJ Jr, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002;87:1020-1025.
27. Goto S, Tamura N, Ishida H. Ability of antiglycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol. 2004; 44:316-323. (Pubitemid 38950589)
28. Quinn M, Deering A, Stewart M, et al. Quantifying GP IIb/IIIa receptor binding using 2 monoclonal antibodies. Circulation. 1999;99: 2231-2238.
29. Scarborough RM, Kleiman NS, Phillips DR. Platelet glycoproteins IIb/IIIa antagonists: what are the relevant issues concerning their pharmacology and clinical use? Circulation. 1999; 100:437-444.
30. Kereiakes DJ. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Rev Cardiovasc Med. 2006;7(suppl 4):S3-S11.
31. van Werkum JW, Gerritsen WBM, Felder HC, et al. Investigating platelet activation with abciximab and high-dose tirofiban in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [abstract]. J Am Coll Cardiol. 2004;43:99A.
32. Mahmud E, Cavendish JJ, Tsmikas S, et al. Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention. J Am Coll Cardiol. 2007;49:2163-2171. (Pubitemid 46817810)
33. Gibson CM, Jennings LK, Murphy SA, et al. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004;110:679-684.
34. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GB IIb/IIIa receptor blockade. Circulation. 1998;97: 1680-1688. (Pubitemid 28211416)
35. Dangas G, Aymong ED, Mehran R, et al. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol. 2004;94:983-988. (Pubitemid 39336427)
36. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358: 2218-2230. (Pubitemid 351724451)
37. Goswami N, Pfeiffer A, Moore A, Mishkel G. HORIZONS in the "real world": use of bivalirudin versus heparin + GP IIb/IIIa inhibitors in ST elevation myocardial infarction [abstract]. Am J Cardiol. 2008;102:49i.
38. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107: 2908-2913.
39. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-171.
40. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the AL-BION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006;48:931-938. (Pubitemid 44292463)
41. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;45: 1392-1396.
42. Hochholzer W, Trenk K, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111: 2560-2564. (Pubitemid 40740853)
43. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49-57.
44. Wöhrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840-1843. (Pubitemid 36444121)
45. Gibson CM, Zorkun C, Kunadian V. Intracoronary administration of abciximab in ST-elevation myocardial infarction. Circulation. 2008;118:6-8.
46. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29:21-30.
47. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63:421-430. (Pubitemid 46426638)
48. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther. 2007;12:205-212.
49. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:e9-e16.
50. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001-2015. (Pubitemid 350106708)
51. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet. 2009;373:723-731.
52. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13:407-413. (Pubitemid 35346941)
53. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006;151:689.e1-689.e10.
54. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527-534.
55. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6: 1153-1159. (Pubitemid 351859125)
56. Ahn HS, Chackalamannil S, Boykow G, et al. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis, and inflammatory diseases. Curr Pharm Des. 2003;9:2349-2365. (Pubitemid 37236356)
57. Moliterno DJ, Jennings L, Becker RC, et al for the TRA*PCI Investigators. Results of a multinational randomized, double-blind, placebocontrolled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Presented at: 56th Annual American College of Cardiology Scientific Sessions; March 24, 2007; New Orleans, LA.
58. Stone GW. Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Paper presented at: 20th Annual Transcatheter Cardiovascular Therapeutics Symposium; October 15, 2008; Washington, DC.
59. Rebeiz AG, Pieper KS, O'Shea JC, et al. 16- to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention [abstract]. Circulation. 2001;104: II-386.